Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial Biotech firm aims to win FDA approval based on study’s results

https://www.statnews.com/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/ By Adam FeuersteinFeb. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.